Hong Kong’s pharma outsourcing stocks shined on Friday. Joinn up over 10%; Wuxi Apptec up 9%; Pharmaron up 8%; Wuxi Bio up 4%.
WUXI APPTEC's 1H25 net profit attributable to shareholders was expected to be RMB8.561 billion, up 101.9% YoY. The revenue was expected to be approximately RMB20.799 billion, up 20.6%, with revenue from continuing operations growing by approximately 24.2%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.